A non-inferiority study of rituximab versus ocrelizumab in relapsing-remitting multiple sclerosis

Authors
Category Primary study
JournalMultiple Sclerosis Journal
Year 2022
This article has no abstract
Epistemonikos ID: b16d0b9d7b8ddb64c361b7a9e527eb507ff7ebb5
First added on: Feb 15, 2025